Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting immunostaining in relation to complex human pathologies.TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding. Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
LSBio has tested and validated monoclonal antibodies (mouse, rabbit, rat), polyclonal antibodies (rabbit, goat, sheep, llama, chicken), and human single and double chain antibodies for use in immunohistochemistry (IHC) using formalin-fixed paraffin-embedded tissues, the most common fixation method used by pathology labs worldwide. After 15 years of experience performing contract IHC research, creating immunohistochemistry localization databases, and producing and testing antibodies in IHC, we have acquired a substantial body of experience regarding IHC and what protocol works with the highest percentage of commercial antibodies and available tissues. Here is our protocol for validating IHC-plus antibodies.
LSBio's IHC-plus™ antibodies have been tested and identified as being optimal for use in immunohistochemistry (IHC) against formalin-fixed paraffin-embedded (FFPE) human tissues under LSBio's standardized IHC-plus™ protocol. Each antibody is tested at multiple concentrations on more than 20 normal human tissue types, and when appropriate, multiple normal brain regions and/or cancer types. LSBio's IHC protocol has been developed over the past 15 years as the most optimal method of immunolabeling FFPE tissues, the most common fixation method used by pathology labs worldwide. A LifeSpan pathologist, with extensive experience evaluating IHC, analyzes the localization profile of each antibody, identifying positive and negative cell types, signal strength, subcellular and extracellular staining, and staining artifacts. This information is then compared with all published expression and localization data available for the protein. This enables LSBio to evaluate how each antibody behaves in IHC, including its specificity to the target protein, its sensitivity of detection, and any non-specific staining characteristics that it may display. In order to be selected as an IHC-plus™ brand antibody, antibodies must have a close correlation to the published literature, be high affinity, display minimal staining artifacts, and have a high signal-to-noise ratio, such that its specific staining is considerably higher than its level of nonspecific background staining. Only the best antibodies receive approval and are given the designation as LSBio's premier IHC-plus™ antibodies.
Learn more about LSBio's Immunohistochemistry (IHC) Validation.